​

Funding Round

Series C - Aldagen

Series C - Aldagen

Investment Firm

Overview

Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.

Announced Date

Sep 01, 2007

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Tullis Health Investors

Tullis Health Investors

Tullis Health Investors is a debt and early_stage_venture and late_stage_venture firm.

CNF Investments, LLC

CNF Investments, LLC

CNF Investments, LLC is a debt and early_stage_venture and late_stage_venture and private_equity and seed firm.

Participant Investors

4

Investor Name
Participant InvestorIntersouth Partners
Participant InvestorCNF Investments, LLC
Participant InvestorTullis Health Investors
Participant InvestorHarbert Growth Partners

Round Details and Background

Aldagen raised $9000000 on 2007-09-01 in Series C

Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 23, 2011
Debt Financing - Aldagen
-1.1M
Jan 13, 2012
Debt Financing - Aldagen
-585.0K
Sep 01, 2007
Series C - Aldagen
4-9.0M
Apr 23, 2008
Series D - Aldagen
4-18.4M

Recent Activity

There is no recent news or activity for this profile.